# Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

> **NCT03636061** · PHASE2 · COMPLETED · sponsor: **Oyster Point Pharma, Inc.** · enrollment: 182 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** OC-01 (varenicline) nasal spray
- **DRUG:** Placebo (vehicle) nasal spray

## Key facts

- **NCT ID:** NCT03636061
- **Lead sponsor:** Oyster Point Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-15
- **Primary completion:** 2018-09-26
- **Final completion:** 2018-09-26
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2021-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03636061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03636061, "Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03636061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*